{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:07Z","timestamp":1753891927932,"version":"3.41.2"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Aim of the study<\/jats:title><jats:p>To evaluate the clinical characteristics and treatment efficacy of patients with severe primary IGF-1 deficiency (PSIGFD) using a recombinant IGF-1 (rhIGF-1).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives of the study<\/jats:title><jats:p>To examine the clinical characteristics of patients with PSIGFD before starting treatment with a rIGF-1. To assess the height changes in patients with PSIGFD, before and after treatment with a rhIGF-1. To analyze the clinical characteristics, side effect frequency, and treatment efficacy with a rhIGF-1 analog in patients with PSIGFD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis was conducted on patients with PSIGFD treated with the rhIGF-1 (mecasermin). Data were collected from patients\u2019 medical records, focusing on the impact of treatment on their growth and monitoring any side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study showed that treatment with rhIGF-1 positively affects growth rate, especially in the first years of treatment. However, the growth rate decreases over time. The change in height from the beginning to the end of the treatment was 0.76\u2009\u00b1\u20090.64 SD, with the first quartile at 0.29 SD and the third quartile at 1.14 SD. During the treatment period, patients\u2019 average body mass increased by 0.37\u2009\u00b1\u20091.35 SD, with the first quartile at \u22120.33 SD and the third quartile at 0.92 SD. Side effects occurred in 50% of patients, with 40% of patients treated with rhIGF-1 experiencing hypoglycemia during treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Treatment with rhIGF-1 is effective in treating patients with PSIGFD, causing significant improvement in growth, but requires continuous monitoring and treatment adjustment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2024.1461163","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T04:39:24Z","timestamp":1730090364000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical characteristics and treatment efficacy in patients with primary severe IGF-1 deficiency treated with recombinant IGF-1"],"prefix":"10.3389","volume":"12","author":[{"given":"Dovile","family":"Denaite","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruta","family":"Navardauskaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000342578","article-title":"Phenotypes, investigation and treatment of primary IGF-1 deficiency","volume":"24","author":"Savage","year":"2013"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1056\/NEJMp038156","article-title":"Insulin-like growth factors and the basis of growth","volume":"349","author":"Rosenfeld","year":"2003","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1530\/EJE-14-0071","article-title":"Characterization and prevalence of severe primary IGF1 deficiency in a large cohort of French children with short stature","volume":"170","author":"Teissier","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/apa.13350","article-title":"Insulin-like growth factor 1 has multisystem effects on foetal and preterm infant development","volume":"105","author":"Hellstr\u00f6m","year":"2016","journal-title":"Acta Paediatr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1210\/edrv.22.1.0419","article-title":"The somatomedin hypothesis: 2001","volume":"22","author":"Le Roith","year":"2001","journal-title":"Endocr Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ghir.2020.01.001","article-title":"Therapy with recombinant human IGF-1 for children with primary insulin-like growth factor-I deficiency","volume":"51","author":"Backeljauw","year":"2020","journal-title":"Growth Horm IGF Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1210\/jcem.77.6.7505286","article-title":"Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome)","volume":"77","author":"Savage","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11154-020-09595-0","article-title":"Laron syndrome\u2014a historical perspective","volume":"22","author":"Laron","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"B9","article-title":"Disorders of growth hormone in childhood","author":"Murray","year":"2000","journal-title":"Endotext"},{"key":"B10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11154-020-09590-5","article-title":"The continuum between GH deficiency and GH insensitivity in children","volume":"22","author":"Savage","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"B11","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1210\/jc.2006-1610","article-title":"Long-Term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity","volume":"92","author":"Chernausek","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5603\/EP.a2018.0074","article-title":"Treatment of severe primary IGF-1 deficiency using rhIGF-1 preparation\u2014first three years of Polish experience","volume":"70","author":"Petriczko","year":"2019","journal-title":"Endokrynol Pol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1530\/EJE-11-0618","article-title":"Diagnosis of endocrine disease: limitations of the IGF1 generation test in children with short stature","volume":"166","author":"Coutant","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B14","first-page":"2","volume-title":"Vaik\u0173 Augimo ir Brendimo Vertinimas","author":"Tutkuvien\u0117","year":"1995"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1210\/jcem-21-11-1440","article-title":"Clinical assessment of body hair growth in women","volume":"21","author":"Ferriman","year":"1961","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"812568","DOI":"10.3389\/fendo.2022.812568","article-title":"Pubertal timing and growth dynamics in children with severe primary IGF-1 deficiency: results from the European increlex\u00ae growth forum database registry","volume":"13","author":"Bang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1002\/ajmg.a.35519","article-title":"Growth standards of patients with noonan and noonan-like syndromes with mutations in the RAS\/MAPK pathway","author":"Malaquias","year":"2012","journal-title":"Am J Med Genet A"},{"key":"B18","doi-asserted-by":"publisher","first-page":"R212","DOI":"10.1530\/EC-18-0099","article-title":"The growth hormone\u2013insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders","volume":"7","author":"Blum","year":"2018","journal-title":"Endocr Connect"},{"key":"B19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ghir.2017.05.007","article-title":"The single IGF-1 partial deficiency is responsible for mitochondrial dysfunction and is restored by IGF-1 replacement therapy","volume":"35","author":"Olleros Santos-Ruiz","year":"2017","journal-title":"Growth Horm IGF Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1530\/EJE-18-0042","article-title":"Phenotypic spectrum and responses to recombinant human IGF1 (rhIGF1) therapy in patients with homozygous intronic pseudoexon growth hormone receptor mutation","volume":"178","author":"Chatterjee","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/B978-1-4557-4858-7.00019-6","article-title":"Disorders of growth hormone\/insulin-like growth factor secretion and action","volume-title":"Pediatric Endocrinology","author":"Backeljauw","year":"2014"},{"key":"B22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fendo.2011.00095","article-title":"Genetic defects in the growth hormone? IGF-I axis causing growth hormone insensitivity and impaired linear growth","volume":"2","author":"Savage","year":"2011","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13023-023-02928-7","article-title":"Challenges in the care of individuals with severe primary insulin-like growth factor-I deficiency (SPIGFD): an international, multi-stakeholder perspective","volume":"18","author":"Backeljauw","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1210\/clinem\/dgad479","article-title":"Frequency and predictive factors of hypoglycemia in patients treated with rhIGF-1: data from the eu-IGFD registry","volume":"109","author":"Bang","year":"2023","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1461163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T04:39:26Z","timestamp":1730090366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1461163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":24,"alternative-id":["10.3389\/fped.2024.1461163"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1461163","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"article-number":"1461163"}}